升主动脉腔内修复:VQI注册研究结果
该研究回顾性分析了VQI注册研究中2013至2022年间44例孤立性升主动脉腔内修复患者,中位年龄76岁,48%为男性。院内死亡率和围术期死亡率分别为23%和27%,估计3年死亡率为40%。结论认为该手术罕见、技术上似乎可行,但围术期并发症和死亡率较高, underlying pathology可能影响结局。
要点
- 升主动脉腔内修复罕见,44例来自19个中心。
- 院内死亡率23%,围术期死亡率27%,3年死亡率40%。
- 主动脉夹层围术期死亡率48%,动脉瘤为0%。
核心结论
- 升主动脉腔内修复罕见,技术上似乎可行,但围术期并发症和死亡率较高。
- 基础病理可能影响高手术风险患者的结局。
- 主动脉夹层的围术期死亡率与既往药物治疗A型夹层的报告相似。
研究设计与样本
- 回顾性分析Vascular Quality Initiative注册研究中2013至2022年接受孤立性升主动脉腔内修复的患者。
- 排除治疗无名动脉或该变量数据缺失的患者。
- 共纳入44例患者,来自19个中心,中位年龄76岁(IQR 66-85岁),21例(48%)为男性。
主要发现
- 病理类型:急性主动脉夹层36%,慢性夹层11%,穿透性动脉粥样硬化性溃疡(PAU)16%,PAU伴壁内血肿2.3%,假性动脉瘤11%,夹层后动脉瘤9.1%,退行性梭形动脉瘤6.8%,囊状动脉瘤6.8%。
- 24例(55%)仅腹股沟入路,13例(30%)经弓上主干入路,8例(18%)植入>1个装置。
- 院内死亡率和围术期死亡率分别为23%和27%;术中1例(2.3%)IB型内漏,1例(2.3%)转为胸骨切开。
- 14例(32%)发生20次术后并发症:急性肾损伤14%、肺部11%、心脏6.8%、再干预6.8%、卒中2.3%、透析2.3%、腿缺血2.3%;估计3年死亡率40%。
关键数值与推荐
- 既往主动脉手术患者围术期死亡率为0%。
- 假性或退行性动脉瘤患者围术期死亡率为0%。
- PAU伴壁内血肿患者围术期死亡率为0%。
- 主动脉夹层、夹层后动脉瘤和PAU的围术期死亡率分别为48%、25%和14%。
- 估计3年死亡率:夹层相关52%,PAU 37%,动脉瘤17%。
临床怎么用
- 升主动脉腔内修复可用于高手术风险患者,但需注意围术期并发症和死亡率较高。
- 基础病理可能影响结局,主动脉夹层患者围术期死亡率较高。
- 未来需要更大样本研究确定该手术的临床安全性,并可能聚焦于专用升主动脉支架的研发。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Endovascular repair of ascending aortic disease represents a last resort alternative for patients at high-risk for open surgery. The aim of this study was to describe outcomes of patients undergoing endovascular repair of the ascending aorta in a large international registry. METHODS: We retrospectively analyzed patients in the Vascular Quality Initiative who underwent endovascular repair isolated to the ascending aorta between 2013 and 2022. Patients with innominate artery treatment or missing data on this variable were excluded. Primary outcomes were in-hospital and perioperative mortality. Secondarily, we assessed in-hospital complications and reinterventions and 3-year mortality with Kaplan-Meier methods. Subset analyses stratified the cohort based on prior aortic surgery and aortic pathology. RESULTS: We identified 44 patients treated at 19 centers, with a median age of 76 years (interquartile range, 66-85 years), and 21 (48%) were males. Pathologies were aortic dissection (acute, 36%; chronic, 11%), penetrating atherosclerotic ulceration (PAU) (16%), PAU with intramural hematoma (2.3%), pseudoaneurysm (11%), post-dissection aneurysm (9.1%), and degenerative fusiform (6.8%) or saccular aneurysm (6.8%). Twenty-six patients (59%) presented symptomatic and two with rupture (4.5%). Almost one-half of procedures were performed within 24 hours (20%) or 4 hours (23%) of presentation or acute decompensation. Twenty-four patients (55%) had groin-access alone, and 13 patients (30%) had supra-aortic trunk access. Eight patients (18%) had >1 device implanted. In-hospital and perioperative mortality were 23% and 27%, respectively. Intraoperatively, there was one (2.3%) type IB endoleak and one (2.3%) conversion to sternotomy. Fourteen patients (32%) had 20 postoperative complications, consisting of acute kidney injury (14%), pulmonary (11%) or cardiac (6.8%), reinterventions (6.8%), stroke (2.3%), dialysis (2.3%), or leg ischemia (2.3%). Estimated 3-year mortality was 40%. Subset analyses found no perioperative mortality in patients with prior aortic surgery (16%), pseudo- or degenerative aneurysm (25%), or PAU with intramural hematoma (2.3%). Differently, perioperative mortality for aortic dissection, postdissection aneurysm, and PAU were 48%, 25%, and 14%, respectively. Estimated 3-year mortality rates differed per pathology group (dissection-related, 52%; PAU, 37%; aneurysm, 17%). CONCLUSIONS: Endovascular repair of the ascending aorta is rarely performed, seems technically feasible, but is associated with considerable perioperative morbidity and mortality. The underlying pathology likely influences outcomes in these high surgical risk patients. Perioperative mortality for aortic dissection is similar to prior reports of medically managed type A aortic dissection. Future research with larger sample sizes is required to determine clinical safety of this procedure and could focus on the development of a dedicated ascending aorta stent graft.
引用
- de Kort JF, Mandigers TJ, Jabbour G, et al. Endovascular repair of the ascending aorta in the Vascular Quality Initiative. J Vasc Surg. 2025. PMID: 40633789. doi:10.1016/j.jvs.2025.06.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。